Table 1—

Demographic, clinical, and laboratory characteristics in 82,958 MHD patients during the 3-year cohort (July 2001 to June 2004, i.e., 12 calendar quarters) including 23,618 diabetic MHD patients who underwent A1C measurement

VariablePatients with diabetes and A1C valuesPatients without A1C values
n23,61856,771
Age (years)63 ± 1360 ± 17
Sex (% women)5044
Diabetes as the cause of ESRD (%)10024
Race/ethnicity (%)
    Caucasian3741
    Black3032
    Hispanic1913
Vintage (time on dialysis, %)
    3–6 months3227
    6–24 months1815
    2–5 years2119
    >5 years3040
Primary insurance
    Medicare (%)6764
Known causes of death
    Cardiovascular (% of all-cause)*5250
    Infectious (% of all-cause)1313
Standardized mortality ratio0.81 ± 0.270.80 ± 0.29
BMI (kg/m2)27.7 ± 6.426.0 ± 5.9
Kt/V (single pool)1.5 ± 0.31.5 ± 0.3
nPCR or nPNA (g · kg−1 · day−1)1.0 ± 0.31.0 ± 0.3
Serum albumin (g/dl)3.67 ± 0.403.76 ± 0.45
Creatinine (mg/dl)7.8 ± 2.89.2 ± 3.5
Ferritin (ng/ml)445 (281)466 (300)
TIBC (mg/dl)205 ± 43203 ± 45
Bicarbonate (mg/dl)21.9 ±2.821.8 ± 3.0
Phosphorus (mg/dl)5.6 ± 1.45.7 ± 1.6
Calcium (mg/dl)9.2 ± 0.79.3 ± 0.8
Blood hemoglobin (g/dl)12.1 ± 1.212.0 ± 1.4
WBC count (×103/μl)7.5 ± 2.37.3 ± 2.5
Lymphocyte (% of total WBC count)20 ± 721 ± 8
  • Data are means ± SD for continuous values if normally distributed and median (interquartile range) if skewed and represent 13-week average measurements during the baseline (first calendar) quarter. P < 0.001 for the difference between the two groups, unless otherwise specified;

  • * P = 0.01;

  • P > 0.05;

  • P = 0.03. ESRD, end-stage renal disease; nPCR, normalized protein catabolic rate; nPNA, normalized protein nitrogen appearance; TIBC, total iron-binding capacity; WBC, white blood cell.